Drugs that contain Fingolimod Hydrochloride

1. List of Gilenya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Mar, 2026

(3 years from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Sep, 2026

(3 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Jun, 2027

(4 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator
Dec, 2027

(4 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Dec, 2027

(4 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(9 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(9 years from now)

Market Authorisation Date: 21 September, 2010

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic